Peter Thompson Biography and Net Worth

Chairman and Co-Founder of Edgewise Therapeutics


Peter Thompson, M.D., serves as a member of our board of directors and is a Partner on the private equity team at OrbiMed, with over 25 years of industry experience. He held executive positions at Becton-Dickinson and Chiron, co-founded and was CEO of Trubion Pharmaceuticals, co-founded Corvus Pharmaceuticals, Cleave Biosciences, Silverback Therapeutics and serves as a director on several company boards. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.

What is Peter A. Thompson's net worth?

The estimated net worth of Peter A. Thompson is at least $2.68 million as of August 23rd, 2024. Dr. Thompson owns 83,695 shares of Edgewise Therapeutics stock worth more than $2,679,914 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Thompson may own. Additionally, Dr. Thompson receives a salary of $76,000.00 as Chairman and Co-Founder at Edgewise Therapeutics. Learn More about Peter A. Thompson's net worth.

How old is Peter A. Thompson?

Dr. Thompson is currently 64 years old. There are 7 older executives and no younger executives at Edgewise Therapeutics. The oldest executive at Edgewise Therapeutics is Dr. Joanne M. Donovan M.D., Ph.D., Chief Medical Officer, who is 67 years old. Learn More on Peter A. Thompson's age.

What is Peter A. Thompson's salary?

As the Chairman and Co-Founder of Edgewise Therapeutics, Inc., Dr. Thompson earns $76,000.00 per year. There are 5 executives that earn more than Dr. Thompson. The highest earning executive at Edgewise Therapeutics is Dr. Kevin Koch Ph.D., President, CEO & Director, who commands a salary of $905,520.00 per year. Learn More on Peter A. Thompson's salary.

How do I contact Peter A. Thompson?

The corporate mailing address for Dr. Thompson and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on Peter A. Thompson's contact information.

Has Peter A. Thompson been buying or selling shares of Edgewise Therapeutics?

Peter A. Thompson has not been actively trading shares of Edgewise Therapeutics during the last quarter. Most recently, on Tuesday, January 23rd, Peter A. Thompson bought 454,545 shares of Edgewise Therapeutics stock. The stock was acquired at an average cost of $11.00 per share, with a total value of $4,999,995.00. Following the completion of the transaction, the director now directly owns 14,436,497 shares of the company's stock, valued at $158,801,467. Learn More on Peter A. Thompson's trading history.

Who are Edgewise Therapeutics' active insiders?

Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.

Are insiders buying or selling shares of Edgewise Therapeutics?

During the last twelve months, Edgewise Therapeutics insiders bought shares 2 times. They purchased a total of 465,402 shares worth more than $5,100,965.10. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 592,545 shares worth more than $11,865,014.27. The most recent insider tranaction occured on September, 23rd when General Counsel John R Moore sold 20,922 shares worth more than $578,074.86. Insiders at Edgewise Therapeutics own 24.1% of the company. Learn More about insider trades at Edgewise Therapeutics.

Information on this page was last updated on 9/23/2024.

Peter A. Thompson Insider Trading History at Edgewise Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/23/2024Buy454,545$11.00$4,999,995.0014,436,497View SEC Filing Icon  
9/16/2022Buy484,496$10.32$4,999,998.7213,981,952View SEC Filing Icon  
See Full Table

Peter A. Thompson Buying and Selling Activity at Edgewise Therapeutics

This chart shows Peter A Thompson's buying and selling at Edgewise Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Edgewise Therapeutics Company Overview

Edgewise Therapeutics logo
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: $32.02
Low: $31.92
High: $32.80

50 Day Range

MA: $30.37
Low: $16.86
High: $36.62

2 Week Range

Now: $32.02
Low: $5.93
High: $38.12

Volume

24,489 shs

Average Volume

944,231 shs

Market Capitalization

$3.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14